2151.00DKK+0.47%Mkt Cap: 19.26B $P/E: 26.58Today
Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with rel…
Industry Peers
BiotechnologyKey Statistics
Company
Market Cap19.26B $
Enterprise Value19.17B $
Revenue (TTM)601.69M $
Gross Profit507.16M $
Net Income (TTM)140.26M $
Revenue/Share9.768 USD
Last Price2151.00 DKK
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees3.1K
CountryDK
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)26.58
P/E (Forward)19.80
PEG5.89
EV/EBITDA95.56
EV/Revenue31.85
P/S32.32
P/B3.31
EPS (TTM)81.78
EPS (Forward)108.13
52W Range
1440.5087% of range2257.00
52W High2257.00 DKK
52W Low1440.50 DKK
Profitability
Gross Margin93.60%
Oper. Margin35.24%
EBITDA Margin33.33%
Profit Margin25.89%
ROE16.47%
ROA7.48%
Growth
Revenue Growth24.90%
Earnings Growth-9.40%
Cash Flow & Leverage
Operating CF172.74M $
CapEx (TTM)8.01M $
FCF Margin21.08%
FCF Yield0.66%
Net Debt548.09M $
Net Debt/EBITDA2.73
Balance Sheet
Debt/Equity0.93
Current Ratio2.46
Quick Ratio2.44
Book Value/Sh646.27 DKK
Cash/Share25.29 DKK
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 DKK
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.5 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)2410.45 DKK
Upside (mean)+12.1%
Target Range1400.00 DKK – 2930.00 DKK
DKK1400.00+12.1% to meanDKK2930.00
# Analysts15
Ownership
Shares Out.61.46M
Float58.96M
Insiders0.00%
Institutions40.22%
Technical
SMA 501847.48 (+16.4%)
SMA 2001867.45 (+15.2%)
Beta0.69
S&P 52W Chg18.16%
Avg Vol (30d)115.21K
Avg Vol (10d)134.82K
Technical Indicators
RSI (14)74.4
MACD76.7046
MACD Signal57.2729
MACD Hist.+19.4316
BB Upper2167.72 DKK
BB Middle1960.50 DKK
BB Lower1753.28 DKK
BB Width21.14%
ATR (14)59.47 DKK
Vol Ratio (20d)1.27x